Literature DB >> 3404983

Complement-mediated pulmonary edema in sheep.

T M Egan1, N R Saunders, S C Luk, J D Cooper.   

Abstract

Incubation of plasma with zymosan results in complement activation. Infusion of zymosan-activated plasma (ZAP) into the pulmonary circulation in sheep results in a transient rise in pulmonary vascular resistance, accompanied by hypoxemia. This is associated with production of the vasoactive prostaglandin metabolite, thromboxane. We hypothesized that ZAP infusion caused pulmonary edema and may transiently alter pulmonary permeability to protein. Two sets of experiments were conducted involving six sheep. Three sheep underwent open lung biopsies during ZAP infusion, and electron microscopy documented early reversible interstitial pulmonary edema in response to ZAP infusion. Three other sheep were prepared with lung lymph fistulae and subjected to a similar infusion of ZAP. These studies documented a rapid rise in lymph flow and lymph protein clearance, occurring immediately upon infusion of ZAP. These experiments demonstrate a rapid reversible interstitial edema in sheep lung in response to ZAP infusion and suggest that permeability to protein may be transiently altered as a result of this injury.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3404983     DOI: 10.1016/0022-4804(88)90066-2

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  2 in total

1.  Multiple organ failure (MOF) after severe trauma--a sheep model.

Authors:  H C Pape; M Grotz; D Remmers; A Dwenger; R Vaske; D Wisner; H Tscherne
Journal:  Intensive Care Med       Date:  1998-06       Impact factor: 17.440

2.  Novel critical role of Toll-like receptor 4 in lung ischemia-reperfusion injury and edema.

Authors:  Giorgio Zanotti; Monica Casiraghi; John B Abano; Jason R Tatreau; Mayura Sevala; Hilary Berlin; Susan Smyth; William K Funkhouser; Keith Burridge; Scott H Randell; Thomas M Egan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-04-17       Impact factor: 5.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.